68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.

Recruiting Phase 2 Interventional Study
Clear Cell Renal Cell Carcinoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
40 (estimated)
Sponsor
Peking Union Medical College Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Radiation therapy (RT) is an effective treatment for patients with advanced-stage clear cell renal cell carcinoma (ccRCC). Current evidence has shown promising outcomes combining radiation therapy and standard systemic therapy in patients with metastatic/recurrent ccRCC. CAIX is a highly sensitive and specific biomarker expressed on ccRCC and in previous studies the investigators have shown excell…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old * Histologically or cytologically confirmed clear cell renal cell carcinoma * Eligible for radiation therapy: no more than 10 lesions in total * Expected survival: over 3 months * ECOG: 0 or 1 * Sufficient organ function * Written informed consent Exclusion…
Contacts

Xianshu Gao, MD

+86 01083575641

gao7777@139.com

CONTACT

Mingwei Ma, MD

+86 0108372408

dr.mingweima@stu.pku.edu.cn

CONTACT